Kimby N. Barton, MSc
Assistant Editor,
Geriatrics & Aging
Last year the reports of the HOPE trial were reported in the New England Journal of Medicine, providing evidence for the role of ACE inhibitors in reduction of primary and secondary outcomes of cardiovascular disease. This month we have decided to profile Dr. Salim Yusuf, who was one of the primary researchers involved in this study and is a scientist recognized worldwide for his contributions to the field of cardiovascular research and for his meta-analytic approaches to clinical trials. Geriatrics & Aging was recently afforded an opportunity to ask Dr. Yusuf some questions regarding his contributions to medicine.
Dr. Yusuf began his illustrious career at St. John's Medical College at Bangalore University in India. He was awarded a Rhodes Scholarship, which took him to Oxford where he obtained a Doctorate in Philosophy. He stayed on as a research fellow working with Professors Richard Peto and Peter Sleight. He trained as a cardiologist in Oxford at the Harefield Hospital, and in 1984 moved to the National Institutes of Health as a scientific project officer. At the NIH, he became project officer of several landmark studies and was Chairman of the Working Group on the Clinical Trial on Women's Health. In September of 1992, Dr. Yusuf took up his current positions as Director of the Division of Cardiology at McMaster University, and as Director of the Preventive Cardiology and Therapeutics Program at the Hamilton Civic Hospitals Research Centre.
Dr.
